A Phase 2 interventional study of FNP-223 and Placebo in Progressive Supranuclear Palsy, sponsored by Ferrer Internacional S.A.. Completed at 44 sites in 9 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Ferrer Internacional S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Supranuclear Palsy, Progressive with a site in United States — 19 open to participants now, 25 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · United States.
Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, this one is the 12th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2024, is one of 11 in phase 2, and was the 73rd registered.
171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.
Browse Supranuclear Palsy, Progressive studies →19 of the 84 studies in Supranuclear Palsy, Progressive with a site in United States are open now. Recruiting first, the newest first:
Prabesh Kanel · Sites in United States
Ages 45+
Adam Boxer · Sites in United States
Ages 41–86
Novartis Pharmaceuticals · Sites in United States, Australia, Belgium and 9 more countries
Ages 41–81
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 40–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 18 · Phase 3 5 · Phase 4 2
First in 1995; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 43 across 102 interventional studies indexed under Supranuclear Palsy, Progressive.
Median enrollment 43 across the 52 interventional studies, 200 across the 31 observational. Of the 54 that completed or were terminated, 9 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 84 have an industry lead sponsor. The 10 most frequent:
Ferrer Internacional S.A. is the lead sponsor of 21 studies on the registry; 2 are open to participants now.
Ferrer Internacional S.A. has 1 study filed under Supranuclear Palsy, Progressive — fewer than ten, so there is no comparison to draw.
8 of the studies in Supranuclear Palsy, Progressive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03872102University of Texas Southwestern Medical CenterFacilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging | 2026-12-31 |
| NCT05913687University of FloridaAutomated Imaging Differentiation of Parkinsonism | 2027-03-31 |
| NCT04468932Oregon Health and Science UniversityTranscranial Magnetic Stimulation in Progressive Supranuclear Palsy | 2027-04 |
| NCT07863180Prabesh KanelTributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial | 2027-05 |
| NCT05459753University of MichiganCholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL) | 2027-06-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of possible or probable PSP of the Richardson's Syndrome (PSP-RS) phenotypes according to the Movement Disorders Society's Progressive Supranuclear Palsy (MDS PSP) clinical features criteria. At least 1 (either 1 or both) of the following 2 items must be met:
Exclusion Criteria:
Non-PSP- RS Movement Disorders or other central nervous system (CNS) Diseases
Procedures
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive FNP-223 orally (PO), 3 times daily (TID).
Drug: FNP-223
Participants will receive matching placebo, PO, TID.
Drug: Placebo
Oral tablets
Oral tablets
Change From Baseline to Week 52 in the PSPRS Outcome
Time frame: Baseline to Week 52
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Clinically significant changes in vital signs, clinical laboratory evaluations, physical examinations, and electrocardiogram (ECG) are included in TEAEs.
Time frame: Baseline to Week 52
Number of Participants Experiencing Serious Adverse Events (SAEs)
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Clinical Global Impression of Severity Scale (CGI-S)
Time frame: Baseline to Week 52
Change From Baseline to Week 52 Participant Global Impression of Severity Scale (PGI-S)
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Caregiver Global Impression of Severity Scale (CaGI-S)
Time frame: Baseline to Week 52
Slope of Decline in PSPRS
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Individual Subitems of PSPRS
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Schwab and England Activities of Daily Living Scale
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in PSP Clinical Deficits Scale (PSP-CDS)
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Montreal Cognitive Assessment (MoCA)
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in PSP Quality of Life Scale (PSP-QoL)
Time frame: Baseline to Week 52
Pharmacokinetic characterization of FNP-223
Mean plasma concentration of FNP-223.
Time frame: At Week 4 and Week 16
Plan to share: No
Ran from Jul 2024 to primary completion in Oct 2026, 26 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Nov 2026 → Oct 2026 and completion Nov 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supranuclear Palsy, Progressive →